EVA Pharma, a leading pharmaceutical company driving healthcare innovation across the Middle East and Africa, has signed a strategic cooperation agreement with the Chaming Qiantang Management Office in Hangzhou, establishing its eighth global office in China's emerging BioPharma Town. The partnership positions the company to leverage China's advanced cell and gene therapy ecosystem while expanding its global footprint in cutting-edge biotechnology.
Strategic Expansion into China's Innovation Hub
The new Hangzhou office will focus on research and development and strategic supply operations in pharmaceuticals, vaccines, and biologics, capitalizing on Qiantang District's robust biopharmaceutical industry resources. According to Riad Armanious, CEO of EVA Pharma, "By anchoring our presence in leading innovation hubs like Hangzhou's Biopharma Town, EVA Pharma is shaping a future where collaboration drives resilience."
The partnership enables EVA Pharma to tap into Hangzhou's position at the forefront of China's cell and gene therapy leadership, supported by significant national investment in the innovation ecosystem. BioPharma Town has attracted a growing number of companies focused on mRNA vaccines, CAR-T therapy, gene editing, and regenerative medicine, supported by cutting-edge academic centers, world-class incubators, and specialized GMP platforms.
Collaborative R&D Focus Areas
Through this partnership, EVA Pharma aims to leverage local capabilities in Hangzhou BioPharma Town while contributing its own R&D expertise, analytical development workflows, and regional regulatory knowledge. The collaboration will explore joint projects in vaccine technology, mRNA applications, and therapeutic biologics, combining EVA Pharma's Middle East and Africa market expertise with China's advanced biotechnology infrastructure.
The company brings significant manufacturing capabilities to the partnership, producing more than one million healthcare products daily at four state-of-the-art manufacturing facilities that have been approved by global and regional regulatory agencies. EVA Pharma's existing research capabilities include mRNA research and development utilizing AI advanced applications for biologic products.
Global Reach and Therapeutic Portfolio
EVA Pharma operates with a 5,000-strong team of professionals and maintains an extensive global presence across more than 70 countries worldwide. The company's product portfolio spans twelve therapeutic areas: anti-infectives, metabolic health, bone, neuroscience, oncology, respiratory, gynecology, urology and andrology, pediatrics, ophthalmology, gastrointestinal tract, and family medicine.
As one of the fastest-growing healthcare companies in the Middle East and Africa, EVA Pharma's expansion into Hangzhou represents a strategic move to access China's advanced biotechnology ecosystem while contributing to global healthcare innovation. The partnership aligns with the company's mission to improve access to high-quality medicines worldwide through its three core pillars: innovation, development, and sustainable access.
